Equities

BIOAGE Labs Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

BIOAGE Labs Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)20.00
  • Today's Change-0.14 / -0.70%
  • Shares traded140.19k
  • 1 Year change+354.55%
  • Beta--
Data delayed at least 15 minutes, as of Feb 20 2026 16:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments3542228
Total Receivables, Net------
Total Inventory------
Prepaid expenses2.750.350.39
Other current assets, total--3.310
Total current assets3572528
Property, plant & equipment, net0.790.520.37
Goodwill, net------
Intangibles, net------
Long term investments0.100.100
Note receivable - long term------
Other long term assets0.2400.03
Total assets3582628
LIABILITIES
Accounts payable2.001.872.26
Accrued expenses126.743.41
Notes payable/short-term debt0390
Current portion long-term debt/capital leases6.006.000.17
Other current liabilities, total8.244.700.02
Total current liabilities28585.86
Total long term debt2.508.202.25
Total debt8.50532.42
Deferred income tax------
Minority interest------
Other liabilities, total4.830.230.15
Total liabilities35678.27
SHAREHOLDERS EQUITY
Common stock0.0000
Additional paid-in capital5768.145.12
Retained earnings (accumulated deficit)(253)(182)(118)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.240.160.17
Total equity323(41)20
Total liabilities & shareholders' equity3582628
Total common shares outstanding363434
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.